Free Trial
NASDAQ:PHIO

Phio Pharmaceuticals 8/14/2024 Earnings Report

Phio Pharmaceuticals logo
$1.98 -0.06 (-2.75%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phio Pharmaceuticals EPS Results

Actual EPS
-$3.62
Consensus EPS
-$4.59
Beat/Miss
Beat by +$0.97
One Year Ago EPS
N/A

Phio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Phio Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Phio Pharmaceuticals' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Phio Pharmaceuticals Earnings Headlines

Trump Knows Exactly What He's Doing
REVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.
See More Phio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email.

About Phio Pharmaceuticals

Phio Pharmaceuticals (NASDAQ:PHIO) engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

View Phio Pharmaceuticals Profile

More Earnings Resources from MarketBeat